An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors.

Trial Profile

An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Pazopanib (Primary) ; Cisplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms PACIFIK
  • Most Recent Events

    • 16 Nov 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov record.
    • 15 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
    • 25 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top